Isolation and characterization of Xenopus soluble epoxide hydrolase

Purba, Endang R.; Oguro, Ami; Imaoka, Shingi

doi:10.1016/j.bbalip.2014.03.010

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the epoxide hydrolases discussed here in mammals and insects, epoxide hydrolases have been identified in a range of organisms, including plants , bacteria , the nematode Caenorhabditis elegans (Harris et al, 2008), and other animals including chickens (Harris et al, 2006) and amphibian Xenopus (Purba et al, 2014). To accommodate new discoveries in the epoxide hydrolase field, it will be necessary to adopt dmd.aspetjournals.org a naming system similar to that generated for the P450 superfamily (Nebert et al, 1987;Nelson, 2006), which currently has at least 20,000 members representing both prokaryotic and eukaryotic organisms (Nelson, 2009).…”

Section: Future Challenges In Epoxide Hydrolasesmentioning

confidence: 99%

The 2014 Bernard B. Brodie Award Lecture—Epoxide Hydrolases: Drug Metabolism to Therapeutics for Chronic Pain

Kodani¹,

Hammock²

2015

Drug Metab Dispos

View full text Add to dashboard Cite

Dr. Bernard Brodie's legacy is built on fundamental discoveries in pharmacology and drug metabolism that were then translated to the clinic to improve patient care. Similarly, the development of a novel class of therapeutics termed the soluble epoxide hydrolase (sEH) inhibitors was originally spurred by fundamental research exploring the biochemistry and physiology of the sEH. Here, we present an overview of the history and current state of research on epoxide hydrolases, specifically focusing on sEHs. In doing so, we start with the translational project studying the metabolism of the insect juvenile hormone mimic R-20458 [(E)-6,7-epoxy-1-(4-ethylphenoxy)-3,7-dimethyl-2-octene], which led to the identification of the mammalian sEH. Further investigation of this enzyme and its substrates, including the epoxyeicosatrienoic acids, led to insight into mechanisms of inflammation, chronic and neuropathic pain, angiogenesis, and other physiologic processes. This basic knowledge in turn led to the development of potent inhibitors of the sEH that are promising therapeutics for pain, hypertension, chronic obstructive pulmonary disorder, arthritis, and other disorders.

show abstract

Section: Future Challenges In Epoxide Hydrolasesmentioning

confidence: 99%

The 2014 Bernard B. Brodie Award Lecture—Epoxide Hydrolases: Drug Metabolism to Therapeutics for Chronic Pain

Kodani¹,

Hammock²

2015

Drug Metab Dispos

View full text Add to dashboard Cite

show abstract

“…In addition to the epoxide hydrolases discussed here in mammals and insects, there have been epoxide hydrolases identified in a range of organisms, including plants (Newman et al, 2005), bacteria (Arand et al, 2003), the nematode C. elegans (Harris et al, 2008) and other animals including chickens (Harris et al, 2006) and amphibian Xenopus (Purba et al, 2014). To accommodate new discoveries in the EH field, it will be necessary to adopt a naming system similar to that generated for the cytochrome P450 (CYP450) superfamily (Nebert et al, 1987;Nelson, 2004), which currently has at least 20,000 members representing both prokaryotic and eukaryotic organisms (Nelson, 2009).…”

Section: Future Challenges In Epoxide Hydrolasesmentioning

confidence: 99%

2014

2018

View full text Add to dashboard Cite

Bernard Brodie's legacy is built on fundamental discoveries in pharmacology and drug metabolism that were then translated to the clinic to improve patient care. Similarly, the development of a novel class of therapeutics termed the soluble epoxide hydrolase (sEH) inhibitors was originally spurred by fundamental research exploring the biochemistry and physiology of the sEH. Here, we present an overview of the history and current state of research on epoxide hydrolases, specifically focusing on sEH. In doing so, we start with the translational project studying the metabolism of the insect juvenile hormone mimic R-20458 which led to the identification of the mammalian sEH. Further investigation of this enzyme and its substrates, including the epoxyeicosatrienoic acids, led to insight into mechanisms of inflammation, chronic and neuropathic pain, angiogenesis and other physiological processes. This basic knowledge in turn led to the development of potent inhibitors of the sEH that are promising therapeutics for pain, hypertension, COPD, arthritis and other disorders.

show abstract